Sign In
Buy ARDS
$0.0001
+0 (+0%)
At Close: Jul 31, 2026
Will Aridis Pharmaceuticals Continue to Surge Higher?
04:08pm, Thursday, 07'th May 2020
As of late, it has definitely been a great time to be an investor Aridis Pharmaceuticals
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, anno
Stocks To Watch: Jobs Report, Virtual Conferences And Blue Chips On Tap
01:09pm, Saturday, 02'nd May 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Aridis Pharmaceuticals to Participate in Maxim Group's Infectious Disease Virtual Conference
09:30am, Wednesday, 29'th Apr 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, anno
Aridis Pharmaceuticals (NASDAQ:ARDS) and Amarin (NASDAQ:AMRN) Financial Comparison
05:32am, Friday, 17'th Apr 2020
Aridis Pharmaceuticals (NASDAQ:ARDS) and Amarin (NASDAQ:AMRN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends
Can Aridis Pharmaceuticals’ APEX Platform Be Used to Target Coronavirus? Analyst Weighs In
06:28pm, Wednesday, 15'th Apr 2020
If nothing else, the COVID-19 pandemic has spurred vast cooperation in the healthcare space. Having said that, it remains unclear as to what approach will be the most effective in stopping the deadly
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
12:35pm, Wednesday, 15'th Apr 2020
The Zacks Analyst Blog Highlights: Pluristem Therapeutics, Mesoblast, Gilead Sciences, Pfizer and Regeneron
Aridis Pharmaceuticals (NASDAQ:ARDS) Research Coverage Started at Maxim Group
07:04am, Saturday, 11'th Apr 2020
Stock analysts at Maxim Group began coverage on shares of Aridis Pharmaceuticals (NASDAQ:ARDS) in a research report issued to clients and investors on Friday, TipRanks reports. The brokerage set a “
Aridis Pharmaceuticals (ARDS) Receives a Buy from Maxim Group
02:12pm, Friday, 10'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Aridis Pharmaceuticals (ARDS) today and set a price target of $17.00. The company's shares
Aridis Pharmaceuticals (ARDS) Receives a Buy from Maxim Group
02:12pm, Friday, 10'th Apr 2020
Maxim Group analyst Jason McCarthy assigned a Buy rating to Aridis Pharmaceuticals (ARDS – Research Report) today and set a
Northland Securities Keeps a Buy Rating on Aridis Pharmaceuticals (ARDS)
10:59am, Thursday, 09'th Apr 2020
Northland Securities analyst Carl Byrnes maintained a Buy rating on Aridis Pharmaceuticals (ARDS) today and set a price target of $22.00. The company's
Northland Securities Keeps a Buy Rating on Aridis Pharmaceuticals (ARDS)
10:59am, Thursday, 09'th Apr 2020
Northland Securities analyst
Carl Byrnes
maintained a
Buy
rating on Aridis Pharmaceuticals (
ARDS
–
Research Report
) today and set a price target of
$22.00
. The company’s shares closed last Wedn
Aridis Pharmaceuticals Announces 2019 Fourth Quarter and Year-End Financial Results and Business Update
08:59pm, Wednesday, 08'th Apr 2020
Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies to treat life-threatening bacterial infections, toda
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
10:45am, Thursday, 26'th Mar 2020
RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation. have filed an Investigational New Drug (IND) Application with the US FDA for a phase 2 trial of RLF-1
RELIEF THERAPEUTICS and NeuroRx, Inc. File FDA IND for Aviptadil to Treat COVID-19-induced Respiratory Distress
10:28am, Thursday, 26'th Mar 2020
RELIEF THERAPEUTICS Holding AG (SIX: RLF) "Relief", together with NeuroRx, a Delaware Corporation, have filed an Investigational New Drug (IND) Application with the US FDA for a phase 2 trial of RLF-1
